Advertisement
Advertisement
U.S. markets closed
S&P Futures
4,219.50 +9.50 (+0.23%) Dow Futures
33,341.00 +81.00 (+0.24%) Nasdaq Futures
13,439.00 +47.00 (+0.35%) Russell 2000 Futures
1,974.40 +4.90 (+0.25%) Crude Oil
91.84 -0.09 (-0.10%) Gold
1,802.60 -11.10 (-0.61%)
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 223.37 |
| Open | 225.33 |
| Bid | 231.85 x 1000 |
| Ask | 236.00 x 3200 |
| Day's Range | 224.40 - 233.88 |
| 52 Week Range | 117.58 - 233.88 |
| Volume | |
| Avg. Volume | 997,419 |
| Market Cap | 27.846B |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.49 |
| Earnings Date | Oct 26, 2022 - Oct 31, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 228.45 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for ALNY
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Alnylam Pharmaceuticals, Inc.Analyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.RatingFair ValueEconomic Moat7 days agoMorningstar
- Barrons.com
Karuna’s Schizophrenia-Trial Data Are ‘Best Case Scenario’ for the Biotech Stock
Analysts said the results were strong enough that the drug could be the go-to treatment once it is approved.
- Investor's Business Daily
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug
Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.
- Investor's Business Daily
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned
A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
